Cerebrospinal fluid biomarker levels are not affected by aspiration or gravity drip extraction methods in Alzheimer’s disease: The AIBL study

Abstract

AbstractBackgroundPrecise analysis of early changes in concentrations of proteins in cerebrospinal fluid (CSF) with qualified immunoassays can reflect the initiation or existence of Alzheimer’s Disease (AD) pathology in brains of affected subjects. Although CSF biomarkers are well established nowadays for use in clinical routine worldwide (eg. NIA AA guideline, FDA qualifications), there is still some ambiguity as to which method should be used to extract the CSF. We aimed to compare in detail potential differences on the most promising protein biomarkers between gravity or aspiration extraction of CSF.MethodsColorimetric ELISA immunoassays, developed by ADx NeuroSciences and commercialised ..